Intra-Cellular Therapies Revenue 2013-2024 | ITCI

Intra-Cellular Therapies revenue for the twelve months ending September 30, 2024 was $0.614B, a 46.08% increase year-over-year.

  • Intra-Cellular Therapies annual revenue for 2023 was $0.464B, a 85.51% increase from 2022.
  • Intra-Cellular Therapies annual revenue for 2022 was $0.25B, a 198.69% increase from 2021.
  • Intra-Cellular Therapies annual revenue for 2021 was $0.084B, a 267.35% increase from 2020.

Intra-Cellular Therapies Revenue 2013-2024 | ITCI

  • Intra-Cellular Therapies annual revenue for 2023 was $0.464B, a 85.51% increase from 2022.
  • Intra-Cellular Therapies annual revenue for 2022 was $0.25B, a 198.69% increase from 2021.
  • Intra-Cellular Therapies annual revenue for 2021 was $0.084B, a 267.35% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$155.8B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$116B
Gilead Sciences (GILD)$111.9B
CSL (CSLLY)$86.5B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.8B
Argenex SE (ARGX)$35.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$25.9B
Biogen (BIIB)$23B
Illumina (ILMN)$21.7B
BeiGene (BGNE)$18.9B
Moderna (MRNA)$14.7B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.5B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.1B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.6B
Exelixis (EXEL)$9.9B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.7B
Revolution Medicines (RVMD)$9.6B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$7.9B
Ascendis Pharma (ASND)$7.4B
Legend Biotech (LEGN)$7.2B